Onkos Surgical

Patrick Treacy, our CEO and Founder, will be sharing the Onkos Surgical story of growth, and disruptive innovation at the 2025 Canaccord Genuity Healthcare Conference. The meeting will be held on Monday, March 10th, at the Westin San Diego Gaslamp at 11am PST. Come learn more about our game-changing portfolio of antibacterial coated implants and new options for revision hip surgery. #onkossurgical #MSTS #AAHKS #AAOS #CanaccordGenuity

Please join us at our educational events at AAOS!

Thank you Orthopedics This Week! NanoCept is a transformative, first-of-its-kind, antibacterial coating for orthopaedic implants. Come see at at the AAOS meeting in San Diego, booth 4629 to learn more. #onkossurgical #NanoCept #revisionorthopedics #MSTS #AAHKS #orthopedicsthisweek #AAOS

Onkos is thrilled to announce a major innovation milestone with the completion of our first cases with NanoCept?, a?groundbreaking antibacterial coating technology for orthopaedic implants.?From our De Novo authorization in April, to the first cases in December of 2024, we are proud to bring this technology to our surgeons and the remarkable patients they care for. With the expansion of capital we announced yesterday, Onkos is well positioned to make another meaningful impact in the area of complex orthopaedic procedures.? Learn more about the groundbreaking NanoCept? first-in-human press release below: https://lnkd.in/e-tSXcfJ CORP 01.11.25 v0 ?? #Innovation #Orthopedics #revision #oncology #NanoTechnology #OnkosSurgical?

Thank you for the shoutout and partnership Horizon!

Onkos is thrilled to announce a major innovation milestone with the completion of our first cases with NanoCept?, a?groundbreaking antibacterial coating technology for orthopaedic implants.?From our De Novo authorization in April, to the first cases in December of 2024, we are proud to bring this technology to our surgeons and the remarkable patients they care for. With the expansion of capital we announced yesterday, Onkos is well positioned to make another meaningful impact in the area of complex orthopaedic procedures.? Learn more about the groundbreaking NanoCept? first-in-human press release below: https://lnkd.in/e-tSXcfJ CORP 01.11.25 v0 ?? #Innovation #Orthopedics #revision #oncology #NanoTechnology #OnkosSurgical?

Onkos is thrilled to announce a major innovation milestone with the completion of our first cases with NanoCept?, a?groundbreaking antibacterial coating technology for orthopaedic implants.?From our De Novo authorization in April, to the first cases in December of 2024, we are proud to bring this technology to our surgeons and the remarkable patients they care for. With the expansion of capital we announced yesterday, Onkos is well positioned to make another meaningful impact in the area of complex orthopaedic procedures.? Learn more about the groundbreaking NanoCept? first-in-human press release below: https://lnkd.in/e-tSXcfJ CORP 01.11.25 v0 ?? #Innovation #Orthopedics #revision #oncology #NanoTechnology #OnkosSurgical?

We’re excited to announce that Onkos Surgical? has partnered with Horizon Technology Finance for a $35 million venture loan facility to support our continued growth and innovation to address complex orthopaedic conditions.?? ?? This funding will allow Onkos Surgical to accelerate the manufacturing and commercialization for NanoCept?, a revolutionary antibacterial coating technology for orthopaedic implants. We are excited to bring this technology to our surgeon customers and the very special patients they care for.??? ?? Learn more via link below: https://lnkd.in/esr95Aiv ?CORP 01.09.25 v0??

Periprosthetic Joint infection is a terrible clinical challenge and growing healthcare economic burden. Ken Urish MD PhD, an adult reconstructive and arthroplasty orthopedic surgeon from the University of Pittsburgh shares more on the dilemma of Periprosthetic Joint Infection. PJI is?associated with a lower survivorship compared to several common forms of cancer and is estimated to burden the healthcare system up to $1.8 billion by 2030. It is also estimated that 60-70% of PJI’s are most commonly initiated at the time of the operation though interoperative contamination.?1,2,3 Do you want to learn how to access the NanoCept? Antibacterial Coating technology? Sign up by using the link below.? https://lnkd.in/ePCXeVZW The NanoCept? coating, where applied, is intended to reduce bacterial contamination on the surface of the coated device components prior to implantation, by killing bacteria that are deposited onto the device surface from the operating environment. The device coating is not intended for the treatment of existing infections or prevention of future infections in patients. The potential clinical impact of bacterial reduction from the NanoCept? coating, including prevention of infection or reduction of infection risk in patients, has not been evaluated in human clinical studies. 1. Zmistowski B, Karam JA, Durinka JB, Casper DS, Parvizi J. Periprosthetic joint infection increases the risk of one-year mortality. J Bone Joint Surg. 2013;95:2177–2184 2. Premkumar et al. Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in the United States. Journal of Arthroplasty 36 (2021)1484-1489 3. Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014 Apr;27(2):302-45. doi: 10.1128/CMR.00111-13. PMID: 24696437; PMCID: PMC3993098. CORP 12.10.24 v0

Happy holidays from our team to yours. We hope you enjoy the peace and joy of this season, and wish you a very safe and prosperous 2025!